ArticleBMC cancer2014

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.

Javier Martinez-Useros et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.